AA
NUVB icon

ALPS Advisors’s Nuvation Bio NUVB Stock Holding History

ALPS Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
282,151
+1,251
+0.4% +$6.97K 0.01% 548
2025
Q4 		$2.52M Buy
280,900
+116,851
+71% +$724K 0.01% 357
2025
Q3 		$607K Sell
164,049
-18,986
-10% -$51.7K ﹤0.01% 634
2025
Q2 		$357K Sell
183,035
-62,091
-25% -$129K ﹤0.01% 854
2025
Q1 		$431K Sell
245,126
-27,024
-10% -$61.5K ﹤0.01% 610
2024
Q4 		$724K Buy
+272,150
New +$701K ﹤0.01% 554

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ALPS Advisors's NUVB Position: Q1 2026 in Review

ALPS Advisors increased its Nuvation Bio (NUVB) stake by 0.45% in Q1 2026, buying an estimated $6.97K and bringing the position to 282,151 shares worth $1.21M. The position accounts for 0.01% of the portfolio, ranked #548.

ALPS Advisors first reported a position in NUVB in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.52M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • ALPS Advisors held 282,151 shares of Nuvation Bio worth $1.21M as of Q1 2026.
  • ALPS Advisors bought 1,251 Nuvation Bio shares in Q1 2026, an estimated $6.97K.
  • Nuvation Bio made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #548 holding.
  • ALPS Advisors first reported a position in Nuvation Bio in Q4 2024 and has held it in 6 quarters since.
  • ALPS Advisors's Nuvation Bio position peaked at $2.52M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.